INTERNATIONAL QUALITY SYSTEMS GUIDANCE DOCUMENT TO BE DEVELOPED BY FDA, EC, CANADA AND JAPAN; TASK FORCE AIMING TO DEVELOP FIRST DRAFT BY SEPTEMBER
Medical device regulators and industry representatives from the U.S., the European Community, Japan and Canada will work together to develop a harmonized guidance document on medical device quality systems, an international government/industry task force agreed at a Jan. 18 meeting in Brussels. As preparation for drafting the international guidance, a study group of the task force will review all guidance documents on quality systems (including drafts) that have been developed by the governments. The task force agreed that appendices on specific issues such as sterilization, software and clean rooms may be necessary. The international document will outline requirements based on the International Standards Organization's 9000 series, which the four governments are adopting as the basis for good manufacturing practices. The EC is beginning to implement medical device directives that incorporate the principals of the ISO standards. FDA plans to propose a revised GMP based on ISO 9001 in the spring. Canada and Japan's GMP development efforts are in earlier stages. The guidance study group's membership has not been finalized, but it is expected that Gordon Higson, chairman of Medical Technology Consultants Europe, Ltd., will lead the group, which is scheduled to meet for the first time on March 4 in Brussels. A draft of the guidance is expected to be completed by the next meeting of the overall task force, which is slated for Sept. 8 in Washington, D.C. The Jan. 18 meeting was the task force's first meeting since being formed at the Third Annual Global Medical Device Conference in September 1992. The group, which is comprised of regulators and industry officials from the U.S., EC, Canada and Japan, is charged with overcoming obstacles to the formation of medical device mutual recognition agreements ("The Gray Sheet" Oct. 12, p. 5). In addition to setting up the study group to formulate the international guidance, the task force agreed to form two additional sub-groups: one that will focus on the harmonization of FDA and EC quality systems requirements and another that will evaluate the potential for harmonization of the product approval programs of the EC, FDA, Japan and Canada. The EC/FDA harmonization group will seek to fine-tune FDA's revised GMP and EC's EN46001 and EN46002 GMP standards to bring them into alignment as both governments finalize the documents. William Hooten, interim director of the Division of Compliance Operations I at the FDA device center's office of compliance and surveillance, will likely be involved in this effort. The product approval group plans to develop a matrix that compares the approval requirements programs of the four governments for a selected group of devices. Harmonizing approval requirements is likely to be more difficult than aligning GMPs because the four governments have greatly differing programs. Although not a major topic at the Jan. 18 meeting, the effort to develop a global medical device standard based on the ISO 9001 standard is ongoing. In December, the Association for the Advancement of Medical Instrumentation submitted a proposal to ISO for the creation of a new technical committee to write the standard. ISO currently is circulating the document among its members and is expected to act on the proposal in the summer.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.
Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.
In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul
Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.
The US’ 90-day suspension of higher “reciprocal tariffs” will expire on 9 July, raising fears that the 31% tariff rate on Swiss medtech and other goods exported to the US might make a comeback. While the tariff situation changes on an almost daily basis, medtechs should forearm for any eventually, say local business organizations.
Guardant Health introduces a new germline panel test to help guide cancer treatment, assess the risk of secondary cancers in patients and identify family members at risk of cancer.